Hydrocodone News and Research RSS Feed - Hydrocodone News and Research

Long-term use of opioids increases risk of new-onset depression

Long-term use of opioids increases risk of new-onset depression

Opioids may cause short-term improvement in mood, but long-term use imposes risk of new-onset depression, a Saint Louis University study shows. [More]
New data shows opioid overdose deaths hit record levels in 2014

New data shows opioid overdose deaths hit record levels in 2014

From 2000 to 2014 nearly half a million Americans died from drug overdoses. Opioid overdose deaths, including both opioid pain relievers and heroin, hit record levels in 2014, with an alarming 14 percent increase in just one year, according to new data published today in CDC's Morbidity and Mortality Weekly Report. [More]
Drug use remains stable among teens, MTF survey shows

Drug use remains stable among teens, MTF survey shows

The 2015 Monitoring the Future survey (MTF) shows decreasing use of a number of substances, including cigarettes, alcohol, prescription opioid pain relievers, and synthetic cannabinoids ("synthetic marijuana"). Other drug use remains stable, including marijuana, with continued high rates of daily use reported among 12th graders, and ongoing declines in perception of its harms. [More]
Stanford study finds that overprescription of opioids goes beyond ‘pill mill’ prescribers

Stanford study finds that overprescription of opioids goes beyond ‘pill mill’ prescribers

Most prescriptions for opioid painkillers are made by the broad swath of U.S. general practitioners, not by a limited group of specialists, according to a study by researchers at the Stanford University School of Medicine. [More]
TSRI researchers awarded $1.6 million grant to advance preclinical studies of potential heroin vaccine

TSRI researchers awarded $1.6 million grant to advance preclinical studies of potential heroin vaccine

Now researchers at The Scripps Research Institute have been awarded a prestigious Translational Avant-Garde Award, which supports the development of medications for substance abuse disorders, from the National Institutes of Health National Institute on Drug Abuse. [More]

Medical researchers use social media to study harmful side effects of narcotics medication

Harnessing the power of social media, medical researchers have sifted through more than two billion tweets and online posts to study the harmful side effects of narcotics medication taken for chronic pain. [More]
FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin. [More]
Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex. [More]
FDA accepts Braeburn's resubmission of Probuphine NDA for review

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action. [More]
Opioids produced by yeast; revealing the potential for cheaper pain relief

Opioids produced by yeast; revealing the potential for cheaper pain relief

Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain. [More]
Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T. [More]
SLU researcher awarded NIH's Cutting-Edge Basic Research Award to solve pain-killer problem

SLU researcher awarded NIH's Cutting-Edge Basic Research Award to solve pain-killer problem

SLU pain researcher Daniela Salvemini has been awarded the NIH's Cutting-Edge Basic Research Award (CEBRA) to solve an alarming problem: pain killers that are capable of quelling terrible pain also carry debilitating side effects and significant risk of addiction. [More]
1 in 4 people with histories of nicotine use, substance abuse likely to use opioid painkillers long-term

1 in 4 people with histories of nicotine use, substance abuse likely to use opioid painkillers long-term

Opioid painkiller addiction and accidental overdoses have become far too common across the United States. To try to identify who is most at risk, Mayo Clinic researchers studied how many patients prescribed an opioid painkiller for the first time progressed to long-term prescriptions. The answer: 1 in 4. People with histories of tobacco use and substance abuse were likeliest to use opioid painkillers long-term. [More]
Veterans who died from drug overdoses also prescribed benzodiazepines for pain

Veterans who died from drug overdoses also prescribed benzodiazepines for pain

In a recent study, nearly half of all veterans who died from drug overdoses while prescribed opioids for pain were also receiving benzodiazepines, or benzos, which are common medications for the treatment of anxiety, insomnia and alcohol withdrawal. Veterans prescribed higher doses of benzodiazepines while concurrently receiving opioids were at greater risk of overdose death than those on lower doses of benzodiazepines. [More]
Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. [More]
BioDelivery Sciences calls for new treatment options for opioid addiction

BioDelivery Sciences calls for new treatment options for opioid addiction

As the rate of opioid abuse soars to new levels, growing recognition of the problem is garnering unprecedented media attention—as well as motivating innovative new approaches to better treatment. [More]

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015. [More]
Neonatal abstinence syndrome on the rise in U.S.

Neonatal abstinence syndrome on the rise in U.S.

The number of infants born in the United States with drug withdrawal symptoms, also known as neonatal abstinence syndrome (NAS), nearly doubled in a four-year period. By 2012, one infant was born every 25 minutes in the U.S. with the syndrome, accounting for $1.5 billion in annual health care charges, according to a new Vanderbilt study published in the Journal of Perinatology. [More]
Prescription painkiller abuse: A worst drug overdose epidemic in history

Prescription painkiller abuse: A worst drug overdose epidemic in history

The Centers for Disease Control calls prescription painkiller abuse "one of the worst drug overdose epidemics in history." [More]
Childbearing women who take painkillers may face increased risk of birth defects

Childbearing women who take painkillers may face increased risk of birth defects

More than one-fourth of privately-insured and one-third of Medicaid-enrolled women of childbearing age filled prescriptions for opioid-based (narcotic) painkillers between 2008 and 2012, according to a new analysis published today by the U.S. Centers for Disease Control and Prevention in its Morbidity and Mortality Weekly Report (MMWR). [More]
Advertisement
Advertisement